FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2794889098> ?p ?o ?g. }

• W2794889098 endingPage "578" @default.
• W2794889098 startingPage "562" @default.
• W2794889098 abstract "Background6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment.MethodsThe SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine. Patients were assigned (1:1) to receive 3 months or 6 months of adjuvant oxaliplatin-containing chemotherapy. The chemotherapy regimens could consist of CAPOX (capecitabine and oxaliplatin) or FOLFOX (bolus and infused fluorouracil with oxaliplatin). The regimen was selected before randomisation in accordance with choices of the patient and treating physician. The primary study endpoint was disease-free survival and the non-inferiority margin was a hazard ratio of 1·13. The primary analysis was done in the intention-to-treat population and safety was assessed in patients who started study treatment. This trial is registered with ISRCTN, number ISRCTN59757862, and follow-up is continuing.Findings6088 patients underwent randomisation between March 27, 2008, and Nov 29, 2013. The intended treatment was FOLFOX in 1981 patients and CAPOX in 4107 patients. 3044 patients were assigned to 3 month group and 3044 were assigned to 6 month group. Nine patients in the 3 month group and 14 patients in the 6 month group did not consent for their data to be used, leaving 3035 patients in the 3 month group and 3030 patients in the 6 month group for the intention-to-treat analyses. At the cutoff date for analysis, there had been 1482 disease-free survival events, with 740 in the 3 month group and 742 in the 6 month group. 3 year disease-free survival was 76·7% (95% CI 75·1–78·2) for the 3 month group and 77·1% (75·6–78·6) for the 6 month group, giving a hazard ratio of 1·006 (0·909–1·114, test for non-inferiority p=0·012), significantly below the non-inferiority margin. Peripheral neuropathy of grade 2 or worse was more common in the 6 month group (237 [58%] of 409 patients for the subset with safety data) than in the 3 month group (103 [25%] of 420) and was long-lasting and associated with worse quality of life. 1098 serious adverse events were reported (492 reports in the 3 month group and 606 reports in the 6 month group) and 32 treatment-related deaths occurred (16 in each group).InterpretationIn the whole study population, 3 months of oxaliplatin-containing adjuvant chemotherapy was non-inferior to 6 months of the same therapy for patients with high-risk stage II and stage III colorectal cancer and was associated with reduced toxicity and improved quality of life. Despite the fact the study was underpowered, these data suggest that a shorter duration leads to similar survival outcomes with better quality of life and thus might represent a new standard of care.FundingMedical Research Council, Swedish Cancer Society, NETSCC, and Cancer Research UK." @default.
• W2794889098 created "2018-04-06" @default.
• W2794889098 creator A5000648403 @default.
• W2794889098 creator A5003117278 @default.
• W2794889098 creator A5010914696 @default.
• W2794889098 creator A5015190461 @default.
• W2794889098 creator A5016495332 @default.
• W2794889098 creator A5018206299 @default.
• W2794889098 creator A5019479654 @default.
• W2794889098 creator A5025282420 @default.
• W2794889098 creator A5026822334 @default.
• W2794889098 creator A5026944178 @default.
• W2794889098 creator A5027160662 @default.
• W2794889098 creator A5028739583 @default.
• W2794889098 creator A5029890517 @default.
• W2794889098 creator A5034457278 @default.
• W2794889098 creator A5035563046 @default.
• W2794889098 creator A5037061841 @default.
• W2794889098 creator A5037978088 @default.
• W2794889098 creator A5040081800 @default.
• W2794889098 creator A5040991512 @default.
• W2794889098 creator A5044651904 @default.
• W2794889098 creator A5047381801 @default.
• W2794889098 creator A5053128035 @default.
• W2794889098 creator A5053677856 @default.
• W2794889098 creator A5054875746 @default.
• W2794889098 creator A5056345420 @default.
• W2794889098 creator A5060521139 @default.
• W2794889098 creator A5063738443 @default.
• W2794889098 creator A5065718203 @default.
• W2794889098 creator A5069879667 @default.
• W2794889098 creator A5072891727 @default.
• W2794889098 creator A5080984611 @default.
• W2794889098 creator A5082554609 @default.
• W2794889098 creator A5083898918 @default.
• W2794889098 creator A5083960633 @default.
• W2794889098 creator A5084536457 @default.
• W2794889098 creator A5090545021 @default.
• W2794889098 date "2018-04-01" @default.
• W2794889098 modified "2023-10-17" @default.
• W2794889098 title "3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial" @default.
• W2794889098 cites W1947168884 @default.
• W2794889098 cites W1960485012 @default.
• W2794889098 cites W1967628954 @default.
• W2794889098 cites W1972370053 @default.
• W2794889098 cites W1994222210 @default.
• W2794889098 cites W2043512623 @default.
• W2794889098 cites W2096571907 @default.
• W2794889098 cites W2098428600 @default.
• W2794889098 cites W2098916599 @default.
• W2794889098 cites W2115012618 @default.
• W2794889098 cites W2118950501 @default.
• W2794889098 cites W2120713475 @default.
• W2794889098 cites W2121627853 @default.
• W2794889098 cites W2138985803 @default.
• W2794889098 cites W2142831070 @default.
• W2794889098 cites W2144495943 @default.
• W2794889098 cites W2146161922 @default.
• W2794889098 cites W2156409369 @default.
• W2794889098 cites W2156813277 @default.
• W2794889098 cites W2167571044 @default.
• W2794889098 cites W2168680994 @default.
• W2794889098 cites W2168816028 @default.
• W2794889098 cites W2171232394 @default.
• W2794889098 cites W2217472701 @default.
• W2794889098 cites W2313857605 @default.
• W2794889098 doi "https://doi.org/10.1016/s1470-2045(18)30093-7" @default.
• W2794889098 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5883334" @default.
• W2794889098 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29611518" @default.
• W2794889098 hasPublicationYear "2018" @default.
• W2794889098 type Work @default.
• W2794889098 sameAs 2794889098 @default.
• W2794889098 citedByCount "119" @default.
• W2794889098 countsByYear W27948890982018 @default.
• W2794889098 countsByYear W27948890982019 @default.
• W2794889098 countsByYear W27948890982020 @default.
• W2794889098 countsByYear W27948890982021 @default.
• W2794889098 countsByYear W27948890982022 @default.
• W2794889098 countsByYear W27948890982023 @default.
• W2794889098 crossrefType "journal-article" @default.
• W2794889098 hasAuthorship W2794889098A5000648403 @default.
• W2794889098 hasAuthorship W2794889098A5003117278 @default.
• W2794889098 hasAuthorship W2794889098A5010914696 @default.
• W2794889098 hasAuthorship W2794889098A5015190461 @default.
• W2794889098 hasAuthorship W2794889098A5016495332 @default.
• W2794889098 hasAuthorship W2794889098A5018206299 @default.
• W2794889098 hasAuthorship W2794889098A5019479654 @default.
• W2794889098 hasAuthorship W2794889098A5025282420 @default.
• W2794889098 hasAuthorship W2794889098A5026822334 @default.
• W2794889098 hasAuthorship W2794889098A5026944178 @default.
• W2794889098 hasAuthorship W2794889098A5027160662 @default.
• W2794889098 hasAuthorship W2794889098A5028739583 @default.
• W2794889098 hasAuthorship W2794889098A5029890517 @default.
• W2794889098 hasAuthorship W2794889098A5034457278 @default.
• W2794889098 hasAuthorship W2794889098A5035563046 @default.
• W2794889098 hasAuthorship W2794889098A5037061841 @default.
• W2794889098 hasAuthorship W2794889098A5037978088 @default.
• W2794889098 hasAuthorship W2794889098A5040081800 @default.

• next